Despite multiple patent expirations of some of its key drugs, including Avastin, Herceptin, and Rituxan, Roche, one of the largest pharmaceutical companies with a market capitalization of close to $300 billion, saw its sales increase from $53.2 billion in 2016 to $64.4 billion in 2019.
Despite multiple patent expirations of some of its key drugs, including Avastin, Herceptin, and Rituxan, Roche, one of the largest pharmaceutical companies with a market capitalization of close to $300 billion, saw its sales increase from $53.2 billion in 2016 to $64.4 billion in 2019.
Share this Article
Comment on this Article
Recommended
Please to comment